Compare Stocks: CLSD, ALZN, MTVA, and IMNN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALZN Alzamend Neuro	$1.80 +1.1%	$1.47	$0.84 ▼ $2.68	$8.69M	0.23	127,718 shs	2,270 shs
CLSD Clearside Biomedical	$0.41	$1.19	$0.37 ▼ $14.09	$2.15M	2.04	220,545 shs	N/A
IMNN Imunon	$1.42 +1.4%	$1.64	$1.39 ▼ $5.64	$7.94M	1.98	96,032 shs	589 shs
MTVA MetaVia	$1.58	$1.60	$0.97 ▼ $14.85	$8.23M	0.94	1.49 million shs	3,080 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALZN Alzamend Neuro	+1.71%	+5.95%	+14.84%	+42.40%	-24.26%
CLSD Clearside Biomedical	0.00%	0.00%	0.00%	0.00%	-89.62%
IMNN Imunon	-4.44%	-9.09%	-15.15%	-24.73%	-74.91%
MTVA MetaVia	-2.47%	-7.06%	+6.04%	-7.60%	-90.42%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALZN Alzamend Neuro	$1.80 +1.1%	$1.47	$0.84 ▼ $2.68	$8.69M	0.23	127,718 shs	2,270 shs
CLSD Clearside Biomedical	$0.41	$1.19	$0.37 ▼ $14.09	$2.15M	2.04	220,545 shs	N/A
IMNN Imunon	$1.42 +1.4%	$1.64	$1.39 ▼ $5.64	$7.94M	1.98	96,032 shs	589 shs
MTVA MetaVia	$1.58	$1.60	$0.97 ▼ $14.85	$8.23M	0.94	1.49 million shs	3,080 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALZN Alzamend Neuro	+1.71%	+5.95%	+14.84%	+42.40%	-24.26%
CLSD Clearside Biomedical	0.00%	0.00%	0.00%	0.00%	-89.62%
IMNN Imunon	-4.44%	-9.09%	-15.15%	-24.73%	-74.91%
MTVA MetaVia	-2.47%	-7.06%	+6.04%	-7.60%	-90.42%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALZN Alzamend Neuro	2.00	Hold	$28.00	1,473.03% Upside
CLSD Clearside Biomedical	1.50	Reduce	N/A	N/A
IMNN Imunon	2.00	Hold	$10.00	614.29% Upside
MTVA MetaVia	2.00	Hold	$20.00	1,165.82% Upside

Current Analyst Ratings Breakdown

Latest CLSD, ALZN, MTVA, and IMNN Analyst Ratings

Date	Company	Brokerage	Action	Rating
8/31/2026	ALZN Alzamend Neuro	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)
8/17/2026	ALZN Alzamend Neuro	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (E+) ➝ Sell (E)
8/3/2026	ALZN Alzamend Neuro	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)
7/21/2026	MTVA MetaVia	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/20/2026	ALZN Alzamend Neuro	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (E+) ➝ Sell (E)
7/17/2026	IMNN Imunon	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/10/2026	MTVA MetaVia	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
6/29/2026	ALZN Alzamend Neuro	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)

(Data available from 9/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALZN Alzamend Neuro	N/A	N/A	N/A	N/A	$1.20 per share	N/A
CLSD Clearside Biomedical	$3.33M	0.64	N/A	N/A	($7.68) per share	-0.05
IMNN Imunon	N/A	N/A	N/A	N/A	$2.30 per share	N/A
MTVA MetaVia	N/A	N/A	N/A	N/A	$2.31 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALZN Alzamend Neuro	-$8.77M	-$2.30	N/A	N/A	N/A	N/A	-277.88%	-184.20%	N/A
CLSD Clearside Biomedical	-$34.35M	-$5.19	N/A	N/A	N/A	-665.19%	N/A	-124.15%	N/A
IMNN Imunon	-$14.49M	-$3.83	N/A	N/A	N/A	N/A	-358.01%	-132.91%	11/12/2026 (Estimated)
MTVA MetaVia	-$12.97M	-$3.23	N/A	N/A	N/A	N/A	-209.67%	-107.91%	11/5/2026 (Estimated)

Latest CLSD, ALZN, MTVA, and IMNN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/10/2026	Q1 2027	ALZN Alzamend Neuro	-$0.56	-$0.68	-$0.12	-$0.68	N/A	N/A
8/11/2026	Q2 2026	IMNN Imunon	-$0.8675	-$0.54	+$0.3275	-$0.54	N/A	N/A
8/6/2026	Q2 2026	MTVA MetaVia	-$0.82	-$0.90	-$0.08	-$0.90	N/A	N/A
7/22/2026	Q4 2026	ALZN Alzamend Neuro	-$0.67	-$0.74	-$0.07	-$0.74	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALZN Alzamend Neuro	N/A	N/A	N/A	N/A	N/A
CLSD Clearside Biomedical	N/A	N/A	N/A	N/A	N/A
IMNN Imunon	N/A	N/A	N/A	N/A	N/A
MTVA MetaVia	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALZN Alzamend Neuro	N/A	3.01	3.01
CLSD Clearside Biomedical	N/A	3.87	3.87
IMNN Imunon	2.86	1.82	1.82
MTVA MetaVia	N/A	2.06	2.06

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALZN Alzamend Neuro	49.61%
CLSD Clearside Biomedical	18.75%
IMNN Imunon	4.47%
MTVA MetaVia	1.37%

Insider Ownership

Company	Insider Ownership
ALZN Alzamend Neuro	1.39%
CLSD Clearside Biomedical	6.70%
IMNN Imunon	2.83%
MTVA MetaVia	0.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALZN Alzamend Neuro	4	4.83 million	4.76 million	No Data
CLSD Clearside Biomedical	30	5.23 million	4.89 million	Optionable
IMNN Imunon	30	5.61 million	5.45 million	Not Optionable
MTVA MetaVia	8	5.16 million	5.13 million	N/A

CLSD, ALZN, MTVA, and IMNN Headlines

Recent News About These Companies

MTVA: Preclinical Findings Support DA-1726 Waist Circumference Reduction

September 10, 2026 | finance.yahoo.com

MetaVia (NASDAQ:MTVA) Trading Up 2.4% - Here's What Happened

September 10, 2026 | americanbankingnews.com

MetaVia annonce des résultats précliniques confirmant le rationnel biologique de la réduction du tour de taille par le DA-1726

September 9, 2026 | zonebourse.comZ

MetaVia Inc.: MetaVia Announces Preclinical Findings Supporting Biological Rationale for DA-1726's Waist Circumference Reduction

September 9, 2026 | finanznachrichten.de

MetaVia Announces Preclinical Findings Supporting Biological Rationale for DA-1726's Waist Circumference Reduction

September 9, 2026 | prnewswire.com

MTVA: Dose Titration Complete in Phase 1 Part 3 Study of DA-1726

August 12, 2026 | finance.yahoo.com

MetaVia Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 6, 2026 | prnewswire.com

MetaVia Inc.: MetaVia Announces Completion of Dose Titration in Phase 1 Part 3 Study of DA-1726 for the Treatment of Obesity

July 9, 2026 | finanznachrichten.de

MetaVia Announces Completion of Dose Titration in Phase 1 Part 3 Study of DA-1726 for the Treatment of Obesity

July 9, 2026 | prnewswire.com

MetaVia Announces $4 Million At-The-Market Stock Offering

July 2, 2026 | tipranks.com

MTVA: Vanoglipel and DA-1726 Data Presented at ADA 2026 Scientific Sessions

June 17, 2026 | finance.yahoo.com

MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum

June 17, 2026 | prnewswire.com

BioStem Technologies Announces Appointment of Three New Members to its Board of Directors

June 9, 2026 | globenewswire.com

MetaVia Shareholders Approve Equity Plan and Reverse Split

June 8, 2026 | tipranks.com

MetaVia Presents New Late-Breaking Obesity and Metabolic Data at the ADA 2026 Scientific Sessions Supporting DA-1726 Differentiation and Vanoglipel Combination Potential

June 8, 2026 | prnewswire.com

MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference

June 4, 2026 | prnewswire.com

MTVA: No evidence for changes in cardiovascular parameters in phase 1 trial of DA-1726

May 28, 2026 | msn.com

MetaVia Presents Higher-Dose Phase 1 Results for DA-1726 at EASL Congress 2026, Supporting Potential in Obesity and MASH

May 27, 2026 | prnewswire.com

Why MetaVia Stock Is Surging On Friday?

May 22, 2026 | benzinga.com

MTVA: Multiple upcoming presentations to highlight DA-1726 and Vanoglipel

May 21, 2026 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLSD, ALZN, MTVA, and IMNN Company Descriptions

Alzamend Neuro NASDAQ:ALZN

$1.80 +0.02 (+1.12%)

As of 09:38 AM Eastern

Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.

Clearside Biomedical NASDAQ:CLSD

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.

Imunon NASDAQ:IMNN

$1.42 +0.02 (+1.36%)

As of 09:38 AM Eastern

Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon's DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase for the development of personalized cancer vaccines or neoepitope cancer vaccines. Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.

MetaVia NASDAQ:MTVA

$1.58 0.00 (0.00%)

As of 09:38 AM Eastern

MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc., formerly known as NeuroBo Pharmaceuticals Inc., is based in CAMBRIDGE, Mass.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CLSD, ALZN, MTVA, and IMNN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CLSD, ALZN, MTVA, and IMNN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CLSD, ALZN, MTVA, and IMNN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLSD, ALZN, MTVA, and IMNN Company Descriptions

Alzamend Neuro NASDAQ:ALZN

Clearside Biomedical NASDAQ:CLSD

Imunon NASDAQ:IMNN

MetaVia NASDAQ:MTVA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CLSD, ALZN, MTVA, and IMNN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CLSD, ALZN, MTVA, and IMNN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CLSD, ALZN, MTVA, and IMNN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLSD, ALZN, MTVA, and IMNN Company Descriptions

Alzamend Neuro NASDAQ:ALZN

Clearside Biomedical NASDAQ:CLSD

Imunon NASDAQ:IMNN

MetaVia NASDAQ:MTVA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools